[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360; 361-380; 381-400; 421-440; 441-460; 461-480

 

NICE TAs 401-420

 

REF

 

TITLE

 

DHFT Formulary link

 

East Midlands Cancer Network link (cancer drugs only)

TA 401

Bosutinib for previously treated chronic myeloid leukaemia          

         


TA 402

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin

   
TA 403

Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer

   
TA 404 

Degarelix for treating advanced hormone-dependent prostate cancer 

8.3 Sex hormones and hormone antagonists in malignant disease
 

 
TA 405

Trifluridine–tipiracil for previously treated metastatic colorectal cancer 

   
TA 406

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

   
TA 407 

Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout

 
TA 408 

Pegaspargase for treating acute lymphoblastic leukaemia

 

N/A - ALL is treated at tertiary centres (NUH is closest) 

TA 409 

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion 

   
TA 410 

Talimogene laherparepvec for treating unresectable metastatic melanoma  

 

Suitable patients to be referred to Leicester as logistical issues (-90C freezer etc)

TA 411 

Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

 

Not recommended

TA 412 

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases 

 

Available – was funded via CDF prior to NICE TA

TA 413

Elbasvir-grazoprevir for treating chronic hepatitis C

5.3 Antiviral drugs

 
TA 414

Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

 

Not recommended

TA 415

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout 

 
TA 416

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

 

Not recommended – available via CDF for the next 2 years whilst additional data is gathered to inform NICE appraisal

TA 417

Nivolumab for previously treated advanced renal cell carcinoma

   
TA 418

Dapagliflozin in triple therapy for treating type 2 diabetes

6.1.1 - 6.1.2.3 Insulin, oral antidiabetic drugs, biguanides

 
TA 419

Apremilast for treating moderate to severe plaque psoriasis

13.5.3 Drugs affecting the immune response   


TA 420

Ticagrelor for preventing atherothrombotic events after myocardial infarction

 

2.9 Antiplatelet drugs